Publication: Initiation of antiretroviral treatment with dual nucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected infants with less advanced disease in a resource-limited setting: A Multi-Center Study in Thailand 1998-2000
Issued Date
2005-08-01
Resource Type
ISSN
01252208
01252208
01252208
Other identifier(s)
2-s2.0-31744440372
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.88, No.SUPPL. 8 (2005)
Suggested Citation
Kulkanya Chokephaibulkit, Nirun Vanprapar, Ruengpung Sutthent, Wanatpreeya Phongsamart, Tawee Chotpitayasunondh, Piyaporn Bowornkitikajorn, Rudeevilai Samkoset, Uraiwan Tarunothai, Sanay Chearskul Initiation of antiretroviral treatment with dual nucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected infants with less advanced disease in a resource-limited setting: A Multi-Center Study in Thailand 1998-2000. Journal of the Medical Association of Thailand. Vol.88, No.SUPPL. 8 (2005). Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/16903
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Initiation of antiretroviral treatment with dual nucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected infants with less advanced disease in a resource-limited setting: A Multi-Center Study in Thailand 1998-2000
Abstract
Objectives: To evaluate the feasibility, duration of efficacy, and outcome of therapy with dual nucleoside reverse transcriptase inhibitors (NTRI) initiated in HIV-infected infants with mild to moderate disease. Material and Method: During 1998-2000, a multi-center prospective open-labeled operational study was conducted. Antiretroviral naôve HIV-infected infants were enrolled in seven hospitals to receive either zidovudine (AZT) plus lamivudine (3TC) or AZT plus didanosine (ddI). Infants who were in CDC stage "C3" were excluded from the study. Results: Of the 88 infants, the mean age of treatment initiation was 6.8 months, and the mean initial CD4 was 1538 cells/mm 3 (21.4%). The z-scores for weight and height increased after 4-8 months of treatment, and by the 24 th month, were +0.89 and +0.69 higher than at enrollment. The CD4% peak increased at 8 months of treatment, by a mean increment of 4.19%, but decreased to the level of 1.08% above baseline by the 24 th month of treatment. Three (3.4%) infants died, 11 (12%) had disease progression, 7 (8%) was prematurely discontinued from the study protocol due to poor compliance, and 37 (42%) were lost to follow-up. At the end of 24 months, all remaining 30 children were in stable condition with a chance of clinical and immunological stability of 34% and 68% by intention-to-treat and on-treatment analysis, respectively. Conclusion: Clinical and immunological benefit from dual NRTI was limited. Treatment of HIV-infected infant with mild to moderate disease in a resource-limited setting may have limited feasibility due to the high drop-out rate.